Crown Bioscience Strengthens Growth Strategy with Appointments as Global Demand Grows for PDX

HOLMES CHAPEL, U.K. - July 2, 2015 - PRLog -- Santa Clara, CA (30th June 2015) – Crown Bioscience, Inc., a leading global drug discovery and development service company, announces five new business developments appointment as part of its continued commitment to offer the world’s largest one-stop collection of PDX models. The ever-increasing demand for Crown Bioscience’s cutting-edge translational platforms and cost-effective drug discovery solutions from its biotech and pharmaceutical partners worldwide is driving the expansion and significant growth strategy of the business. The appointments reinforce Crown’s on-going strategy to increase the company’s visibility as the dominant global provider of Translational Oncology drug discovery services and preclinical CRO services in Asia, the USA and Europe.

Crown Bioscience prides itself on understanding its customers’ research needs and is acutely aware that each research area of oncology has its own opportunities and challenges, specifically the area of cancer immunotherapy. With the capacity to develop and deliver diverse PDX models at an unprecedented scale, the new business development roles join an already established worldwide management team based in the US, Europe, Asia and France.

Responsible for a diverse range of specialist platforms, the new appointments will sit within the Business Development team. Crown’s new business development managers will reinforce the company’s presence in Europe, especially in France, Central Eastern Europe and the UK, as well as in Israel, the East Pacific Asia, the US east coast, and Brazil, to ensure all clients’ drug discovery and development needs are met and to further strengthen its global presence, adding assets, local expertise and support.

The new appointmentsbring with them a combined total of more than 30 years’ global experience in the pharmaceutical drug discovery and development services sector. “We see these key appointments as a major step in the next phase of our growth as a global provider of preclinical CRO services,” comments Jean Pierre Wery, president of Crown Bioscience.

“Their understanding and experience of the pharmaceutical industry will be invaluable as we continue to build our global presence, helping our clients to improve clinical outcomes for patients. They join the Business Development team with the objective of supporting our clients’ research needs, speeding up the process of helping each customer find the research solution that best suits their specific challenge.”

This recruitment drive follows the recent appointment of Laurie Heilmann as senior vice president of global strategy, marketing and business development. “It’s an exciting time to join Crown Bioscience as it continues to pursue an ambitious growth strategy for translational service platforms. These important additions to the team offer impressive business development credentials and I am looking forward to harnessing their experience to create real value and recommend innovative research solutions for our customers as part of our strategic vision to drive forward our global operations.”

Crown Bioscience’s unique, clinically relevant models reflect the patient situation for each aspect of cancer progression, encompassing pre-cancerous lesions, primary tumors and metastasis, as well as being ethnically diverse and representing both treated and drug naïve patients. Clients can access a unique resource of relevant models containing clinically proven molecular markers present in global populations. Crown Bioscience has the ability to run hundreds of models in parallel, enabling clients to complete avatar trials in months rather than years to determine the genetic signature of responders versus non-responders. This enables drug discovery companies to make better informed decisions regarding the selection of patients and the design of clinical trials to ultimately reduce the attrition of compounds in the clinic.